The companies plan to work collaboratively with the goal of improving patient outcomes through personalized medicine. Transgenomics’s highly sensitive technologies for DNA mutation detection and analysis are expected to complement and enhance Coxen, which combines genomic and pharmacological response data on a set of widely used cancer cell lines to generate molecular signatures of patient response to specific anti-cancer agents.
This test is intended to provide the optimal therapy recommendation according to the molecular characteristics of each patient’s tumor.
Tim Gallagher, CEO of Key Genomics, said: “Coxen has the potential to bring significant healthcare and economic value by personalizing cancer therapy by using such a method, an algorithm based on in vitro response to anti-cancer drugs.”